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ABSTRACT 
The ubiquitin proteasome system (UPS) regulates numerous cellular functions by 
selectively degrading cellular proteins. It controls activation of the transcription factor 
NF-ĸB which is involved in the expression of pro-inflammatory mediators. The UPS 
regulates neuronal signalling by controlling levels of synaptic proteins during chronic 
pain. 
Pain and inflammation are the major components of inflammatory joint disorders. The 
focus of this thesis has been to further investigate mediators of pain and inflammation 
and to explore the role of UPS in pathogenesis of chronic arthritic conditions such as 
the rat models of rheumatoid arthritis (RA) and osteoarthritis (OA).  
Opioid peptides dynorphins are involved in the maintenance of pathological pain. The 
localization and distribution pattern of dynorphins precursor protein prodynorphin 
(PDYN) was studied in the brain. We could demonstrate that high levels of PDYN 
were present in the amygdala, hippocampus and stratum and lower amounts in the 
cerebral cortex. Furthermore, PDYN was detected in the ventral trigeminal area and in 
the hypocampal CA3 regions that do not have cell bodies of PDYN-producing neurons 
but contain axons and axon terminals. PDYN is thus transported to and stored in axon 
terminals prior to release from secretary granules as mature peptides. Furthermore, we 
could demonstrate that the depolarization of neuronal cells stimulates processing of 
PDYN into mature dynorphins which may represent the local regulation of synaptic 
transmission.  
The UPS regulates the processing and secretion of dynorphins and CGRP during 
neuropathic pain. We investigated the role of UPS in pain and inflammation in 
adjuvant arthritis by the using proteasome inhibitor MG132. We demonstrated an 
increased expression of p50 (a subunit of NF-κB) and NF-κB activity in arthritic joints. 
A decrease in p50 expression and in NF-κB activity was observed and coincided with 
reduced arthritic severity when MG132 was administered. Furthermore, an increased 
expression of SP and CGRP was observed in arthritic joints to correspond with 
increased pain. MG132 therapy reversed the up-regulated expression of SP and CGRP 
in the arthritic joints and of SP and PDYN in both the dorsal root ganglia (DRG) and in 
the spinal cord (SC). These results suggest that the UPS regulates pain and 
inflammation at the peripheral tissues. UPS-mediated protein regulation in the 
peripheral and central nervous system most likely also regulates inflammatory and 
nociceptive mediators.  
In addition, the role of UPS in the mediation of pain and disease progression was 
studied in OA. Pain mechanisms in OA are unclear but the sensitization of nociceptors 
in the synovium and bone probably contributes to the initiation and maintenance of 
pain. We demonstrated that the decreased pain thresholds were related to the increased 
expression of SP and CGRP in the knee joint and in corresponding DRG. We observed 
an enhanced expression of matrix metalloproteinase-3 (MMP-3) in the knee joints that 
coincided with pathological changes in the OA cartilage. MG132 administration caused 
a significant reversal of pain behavior, attenuated cartilage and bone destruction and 
resulted in a decrease in SP, CGRP and MMP-3 expression in knee joint.  
In conclusion, the UPS represents a major intracellular pathway that critically regulates 
the development of both joint inflammation and inflammatory pain. In future 
perspectives, novel safe proteasome inhibitors with limited adverse side-effects would 
be available with the benefit of targeting both pain and inflammation. 
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1 INTRODUCTION 
 
Due to demographic changes there is a continuous increase in the proportion of elderly 
people with disabling and degenerative disease. For the vast majority of these patients, 
pain is the predominant symptom and the main reason for disability, regardless of 
whether the underlying disease is rheumatoid arthritis, osteoarthritis, fibromyalgia, 
osteoporosis or skeletal metastasis. The mechanisms underlying pain are still not clear.  
 
To date, the prevailing means of preventing and treating painful and inflammatory 
conditions have been unable to offer satisfactory solutions. Physiotherapy and surgery 
for being expensive and therapeutically of limited value are unable to meet the 
demands. Surgical interventions such as joint replacement are an effective treatment for 
joint destruction (1). One has to remember that joint replacement does not last forever 
and that revision surgery is very demanding (2). There are also several diseases such as 
fibromyalgia for which there is no indication for surgery. Pharmacotherapy, possibly in 
combination with the others, is presumably the one realistic option in resolving the 
problem in a wider perspective. Until now, Pharmacotherapy in chronic pain 
conditions, however, has only been useful for patients with slight-to-moderate 
symptoms, partly because of the side-effects at higher doses. Thus the patients in 
greatest need of pain relief, constituting a major proportion, are left without a viable 
alternative except for a small subset that is suitable for surgical intervention. There is 
therefore an urgent need of more effective pharmacotherapy. 
 
The aim of this thesis work has been to identify mediators of pain and inflammation in 
inflammatory joint diseases and to study the effect of the reversible proteasome 
inhibitor MG132 on these mediators with special reference to rheumatoid arthritis (RA) 
and osteoarthritis (OA), two most common joint disorders, using animal models.  
 
1.1 RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease that primarily 
affects the joints. The functional disability that results from progressive joint 
destruction is associated with substantial cost, significant morbidity and premature 
mortality. RA affects about 0.5 -1% of the population. Women are affected 2-to-3 times 
more often than are men. Onset of the disease can be at any age but is most frequent in 
35-to-50 year olds. RA has a worldwide distribution with a notable low incidence in 
Africa and Asia, and a high prevalence in Europe as well as in Native American 
populations (3, 4).  
 
1.1.1 Etiology 
 
Although RA involves autoimmune reactions, the precise cause is still unknown. Both 
genetic and environmental factors have been identified to play a role in RA 
susceptibility. The most important genetic risk factors are linked to the class II major 
histocompatibility complex (MHC) on chromosome 6 (5, 6) and to a non-MHC gene 
tyrosine phosphatase non-receptor type 22 (PTPN22), a gene that regulates T-cell 
activation and increases RA risk by 40-80% (7). Not only genetic but also 
environmental factors such as smoking, diet, and birth weight and socioeconomical 
status are some of the features identified as risk factors for RA (8-10). Combination of 
genetic factors along with smoking further increases the risk for RA (8). 
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1.1.2 Symptoms 
 
In RA general disease features include fatigue, lack of appetite, low-grade fever, 
muscles and joint stiffness. In RA, multiple joints are involved which become swollen, 
painful and tender due to synovitis and destruction of cartilage and bone.  
RA is clinically a heterogeneous disease, with no single diagnostic or pathological 
symptoms. Diagnostic criteria was developed by the American College of 
Rheumatology (ACR) in 1987 and used for clinical diagnosis of RA and also serve as 
the classification criteria for RA (Table 1). 4 out of 7 criteria should be fulfilled to 
establish the diagnosis of RA. 
 
Table 1. The ACR classification criteria for RA 
Morning stiffness for at least one hour and present for at least six weeks 
Swelling of three or more joints for at least six weeks 
Swelling of wrist, metacarpophalangeal, or proximal interphalangeal joints for at least 
six weeks 
Symmetric joint swelling 
Radiographic changes  
Rheumatoid subcutaneous nodules 
Rheumatoid factors 
 
 
1.1.3 Pathophysiology of RA 
 
RA is characterized as the disease of the synovial membrane.  In normal joints the 
synovial membrane that lines the non-weight-bearing surface of joints is thin and 
comprises two layers and produces lubricating and nourishing synovial fluid. Within 
the synovia, resident cells are macrophage-like synoviocytes, fibroblasts-like 
synoviocytes, nerve fibres and adipocytes. During RA synoviocytes proliferate and 
inflammatory cells are recruited from the blood and synovial membrane thickened to 6-
8 layers or more (Figure 1). 
 
 
 
Figure 1. Pathophysiological changes in the RA joint 
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Macrophages play a crucial role in RA. Activated macrophages produce prostaglandins 
and other inflammatory mediators including IL-1 and TNF-α and up-regulate MHC-
class II in response to stimuli. Plasma cells in inflamed synovial membrane produce 
large quantities of immunoglobins including autoantibodies such as RF. T lymphocytes 
are present within the deeper layers of the synovium. Activated T lymphocytes produce 
certain cytokines such as IL-17 which can be detected both in the synovial fluid and 
synovial membrane.  
Cytokines are key players in pathogenesis of RA. Synovial fluid contains large 
quantities of cytokines secreted by macrophages, dendritic cells, neutrophils and 
synovial fibroblasts. Cytokines such as TNF-α, IL-1 and IL-17 stimulate the production 
of destructive proteases, Matrix metalloproteinases (MMPs) which break down 
collagen and have been implicated in joint destruction. The inflamed synovium forms a 
pannus tissue, which grows into the articular cartilage and cause bone destruction. Bone 
destruction first appears as marginal erosions at the site of synovial proliferation, where 
bone is unprotected by hyaline cartilage. Subsequent bone destruction leads to 
sublaxation and deformity. 
 
1.1.4 Therapies 
Therapies include NSAID drugs, systemic administration or intra-articular injections of 
corticosteroids, disease modifying anti-rheumatic drugs and specific antagonists against 
TNF-α or IL-1 provide efficient treatments to many but not to all RA patients (Table 2). 
The search for more beneficial therapies is still warranted. 
  
Table 2. Therapies available for treatment of RA. 
NSAIDs Non-steroidal anti-inflammatory drugs. Analgesic and 
mild-anti-inflammatory effect. Do not alter the disease 
course or prevent joint destruction 
Corticosteroids Anti-inflammatory mechanism.  Prevents joint damage. 
DMARDs Disease modifying anti-rheumatic drugs. Halt or retard 
progression of disease. Methotraxate, sulphasalazine, 
gold salt, chloroquine and cyclosporine A. 
Biological Antagonists including mAb and soluble receptors 
against endogenous proinflammatory mediators. TNF 
blocker (infliximab, etanercept, adalimumab), rIL-1 
receptor antagonist, IL-6 R blocking mAb, anti-CD20 
mAb. 
 
 
1.2 OSTEOARTHRITIS 
Osteoarthritis (OA) is the most common form of arthritis and a leading cause of chronic 
disability worldwide. OA can affect any joint but the most frequently affected sites are 
the hands, knees, hips, and spine (11). Clinically significant osteoarthritis of the knee, 
hand, or hip occurs in 8.9% of the adult population with knee OA as the most common 
type (6% of all adults) (12, 13). The prevalence of OA in middle-aged people causes 
society a considerable burden due to loss of working time and early retirement. OA is 
the most common reason for total knee and hip replacement (14).  
 
Osteoarthritis is classified as being primary or secondary. Primary OA is age-related 
and is common among the older population. Constitutional factors are of importance 
for the development of primary OA. Medical conditions such as trauma, abnormally 
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formed joints, hip dysplasia, diabetes, and inflammatory chronic arthritis may cause 
development of secondary osteoarthritis. The symptoms are similar to those of primary 
osteoarthritis. 
 
1.2.1 Etiology 
A number of risk factors such as mechanical injury, obesity, peripheral neuropathy, 
genetic factors and increasing age have been identified, and interaction of these risk 
factors is known to initiate this musculoskeletal disorder but still the exact etiology is 
not known (14). 
 
Obesity is considered as one of the most important risk factors for OA, especially for 
OA manifest in knees. High BMI (>30) is associated with knee OA but not with hip 
OA (15). Several studies indicate a role of genetic factors in an earlier onset of OA. 
Twin studies in females have revealed that the influence of genetic factors in hand OA 
may approach up to 70% (16). Candidate gene studies and genome-wide linkage 
analyses have revealed polymorphisms or mutations in genes encoding extracellular 
matrix molecules (type II collagen (COL9A1), Aggrecan (AGC1)) and signalling 
molecules (Bone morphometric protein (BMP5), vitamin D receptors (VDR)) (17, 18). 
In contrast to RA, no MHC class II associated gene has been identified. 
 
The likelihood of developing osteoarthritis increases with age. The prevalence of 
having knee OA is negligible between 25-34 years of age and increases to 20-40% in 
those aged 75 and older (19, 20). The prevalence is higher in men than in women up to 
approximately age 45; after 45 it is reversed and by 65 years of age and over the 
female: male ratio ranges from 1.5:1 to 2:1 (11). Hip osteoarthritis is less common than 
knee osteoarthritis but symptoms are often severe. Population-based radiographic 
surveys of patients aged 55-74 revealed an increase in prevalence with age, with 16% 
in men and 6% in women (19, 21).   
 
1.2.2 Symptoms 
OA symptoms are often associated with significant functional impairment, as well as 
signs and symptoms of pain, inflammation, joint stiffness and deformity, and loss of 
mobility (13). These symptoms may develop in one or more joints. Pain symptoms are 
increased when the joint is loaded. With progression of disease the pain can occur at 
rest.  
 
Diagnostic evaluation includes patient history, physical examination, radiological 
examination and in some cases laboratory testing. The clinical symptoms and signs of 
osteoarthritis and its radiological correlates follow a typical course of disease 
progression and can be incorporated into a clinically useful staging system. A number 
of different joint-specific scoring systems have been developed which differ from each 
other in subjective and objective criteria (22).  
 
The Histological-Histochemical Grading System (HHGS) originally proposed by 
Mankin in 1971 is a commonly used grading system for evaluation of osteoarthritic 
cartilage (23). Originally developed for the assessment of human articular cartilage it 
has also been used for grading of animal cartilage destruction (22). Although frequently 
used the HHGS score has been criticized for its questionable reproducibility and 
inadequate assessment (24, 25). In 2006 the Osteoarthritis Research Society 
International (OARSI) developed an alternative Osteoarthritis Cartilage Histopathology 
Assessment System (26). The OARSI system emphasizes the extent of cartilage 
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damage over the articular surface through different stages over disease development, in 
addition to damage analyzed at several levels of the cartilage layer (26) 
 
1.2.3 Pathophysiology 
Recent advances in image techniques (MRI) indicate OA as a disease of the entire joint. 
The pathophysiology of OA involves not only the breakdown of articular cartilage but 
also changes in the subchondral bone and synovium (27). The cartilage has received 
most attention in past years due to extensive damage evident in pathology specimens 
and from imaging studies.  
Human articular cartilage is continuously remodelled as a result of anabolic and 
catabolic processes. The chondrocytes in normal adult cartilage maintain a balance 
between synthesis and degradation of extracellular matrix components. The metabolic 
activity of the chondrocytes in OA is shifted toward a state where new matrix synthesis 
is outweighed by the breakdown of matrix constituents, with an increased production of 
catabolic cytokines and matrix-degrading proteinases. Loss of joint surface integrity 
occurs as a result, and cartilaginous vertical clefts develop (fibrillation), deeper lesions 
exposing the subchondral bone. The exposed bony surface can have necrotic lesions 
that lead to the formation of bone cysts. Simultaneously, angiogenesis of subchondral 
bone marrow as a result of the initial insult to the bone tissue causes calcification of the 
affected cartilage that stimulates endochondral ossification (osteophytes) (27, 28).  
 
In addition to the articular cartilage the synovium will be infiltrated with inflammatory 
mediators. Ligaments  that are often lax, and bridging muscles, become weak and the 
neuromuscular apparatus may also display pathophysiological changes.  The 
classification of OA as a non-inflammatory process is in part due to the low synovial 
fluid leukocyte  counts. In contrast, the clinical signs (i.e. swelling, effusions and 
stiffness) clearly reflect synovial inflammation. While environmental and genetic 
factors influence the incidence and progression of OA, the damage incurred by joint 
tissues is mediated by a variety of cytokines, growth factors, proteases and 
inflammatory mediators  released by the chondrocytes and synoviocytes (Figure 2) (29, 
30). 
 
 
 
 
 
Figure 2. Pathophysiological changes in the osteoarthritic knee joint, modified from 
reference (27) 
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1.2.4 Therapies 
Osteoarthritis is not a curable disease at present, as the mechanism by which it arises 
and progresses remains incompletely understood. The goal of treatment is therefore to 
alleviate the signs and symptoms of the disease and, if possible, to slow its progression. 
The therapeutic spectrum ranges from conservative treatments such as physiotherapy, 
orthopedic aids and orthosis, pharmacotherapy and finally surgery. 
 
The most widely used drugs are NSAIDs which provide incomplete relief in chronic 
patients (31). A number of new agents, referred to as disease-modifying osteoarthritic 
drugs (DMOADs) are now the subject of preclinical and clinical trials (e.g. Risedronate 
(bisphosphonates)). Imaging data indicate that it fails to stop OA disease progression, 
despite improvement of symptoms and reduced cartilage degradation markers (such as 
CTX-II) in both a 1-year study (32) and a 2-year multinational phase III trial of 2400 
knee OA patients (33). There is thus a need for more effective pharmacotherapies to 
mitigate disease progression as well as pain. The classes of medications used to treat 
osteoarthritis (Table 3). 
 
Table 3. Agents Used to Treat Osteoarthritis (34) 
Oral non-opioid analgesica (eg, Acetaminophen) 
Topical NSAIDs (e.g. capsaicin cream) 
NSAIDs 
Intra-articular steroid injections  
Opioid anelgesics 
 
 
1.3 PAIN 
Pain has been defined as an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage (35). Mechanical, thermal or chemical damage to 
the tissue sensitizes pain receptors (nociceptors) on primary afferent neurons which 
transmit a signal along the spinal cord to the brain. This process involves a variety of 
autonomic responses and is called nociception and causes the perception of pain.  
 
1.3.1 Types of pain 
According to the pathogenesis, pain can be classified as: 
 
1.3.1.1 Nociceptive pain 
Nociceptive pain is initiated by the stimulation of nociceptors as a result of tissue injury 
and/or inflammation. Nociceptive pain can be further divided into somatic and visceral 
pain. Somatic pain can be superficial or deep somatic pain. Superficial somatic pain is 
initiated by the activation of nociceptors in the skin or superficial tissues. Deep somatic 
pain is initiated by the stimulation of nociceptors in ligaments, tendons, bones, blood 
vessels or in muscles. Visceral pain originates in the viscera (organs) and is extremely 
difficult to locate. Several visceral regions produce ‘referred’ pain when injured, where 
the sensation is located in an area distant from the site of injury or pathology. 
    7
1.3.1.2 Neuropathic pain 
Neuropathic pain is caused by the injury or disease of neurons. It is defined as 
peripheral neuropathic pain if the injury is in the peripheral nervous system and 
central neuropathic pain if the neurons in the central nervous system are effected (36).  
In many cases pain is not strictly inflammatory or neuropathic because neuropathy may 
involve inflammatory components and neuropathic components may contribute to 
inflammatory pain states (37). Pain can be distinguished as being acute or chronic pain, 
the latter reflecting pain experienced in excess of 6 months (38). 
 
1.3.2 Pain system 
Pain transduction and perception is an extensive and complex process involving 
fundamental biological events at multiple levels of the nervous system. Noxious stimuli 
activate primary afferent neurons with free nerve endings.  Primary afferent nerve 
fibres can be classified into three types on the basis of their diameter, structure and 
conduction velocity. 
C-fiber C-fibers have unmyelinated axons with a diameter ranging from 0.4-1.2 µm, 
conduct action potentials slowly at a rate of 0.5 to 2.0 m/sec, and have small-diameter 
cell bodies. C-fibers mediate the slower, burning quality of pain. C-fibers comprise 
approximately 70% of all nociceptors. A variety of neuropeptides, including substance 
P (SP) and calcitonin gene-related peptide (CGRP) have been identified in C-fibers.  
Aδ-fiber Aδ-fibers have lightly myelinated axons, with a diameter ranging from 2-6 
µm, conducting nerve impulses at a rate of 12 to 30 m/sec, and have medium-sized cell 
bodies 
Aβ-fiber Aβ-fibers have myelinated axons, with a diameter ranging > 10 µm, 
conducting nerve impulses at a rate of 30-1000 m/sec and have large-sized cell bodies. 
Aβ-fibers mediate the fast, pricking quality of pain.  
 
Cell bodies of C- and A-fibre neurons are located within the peripheral sensory ganglia 
such as dorsal roots (DRG). DRG neurons have very long t-shaped axons with one end 
forming a sensory terminal at the skin or viscera and another end synapsing in the 
dorsal horn of the spinal cord. In the spinal cord these neurons project to the outermost 
region of the spinal dorsal horn (lamina I and outer lamina II) and terminate largely on 
spinal neurons that project to higher-order pain centers such as the cortex and the 
hypothalamus in the brain.  
 
1.3.3 Mediators of pain 
Several classes of neurotransmitters and neuromodulators present in the primary 
afferent fibres, spinal dorsal horn and in brain regions are suggested to involve in 
nociception.  These include excitatory amino acids (glutamate and aspartate), sensory 
and autonomic neuropeptides (SP, CGRP, NKA, and CCK), prostaglandins, 
bradykinin, nitric oxide (NO) and adenosine in the primary afferent fibres (40-42). In 
the dorsal horn of the spinal cord, neurotransmitters (e.g., glutamate, SP and CGRP) 
from the primary afferent terminals and on the post-synaptic membrane, neuropeptides 
(e.g., SP, CGRP and dynorphins) and their receptors (e.g, glutamate receptors, NMDA, 
AMPA) participate in central sensitization (43, 44).  
 
1.3.3.1 Sensory neuropeptides 
Sensory neuropeptides, SP and CGRP are synthesized in neurons of dorsal root ganglia. 
Almost 90 % of SP is transported distally (45). Apart from it nociceptive role, SP has 
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also been found to participate in proinflammatory mechanisms. CGRP is often 
localized with SP in unmyelinated C fibre facilitates the release of SP at the spinal cord 
level and delay SP degradation and potentiate the nociceptive effect. 
 
1.3.3.2 Dynorphins 
dynorphin A, dynorphin B, and α-neoendorphin, collectively known as dynorphins are 
cleaved from the precursor protein prodynorphin (PDYN) (46). These peptides can be 
metabolized into shorter forms such as Leu-enkephalin-Arg6 and Leu-enkephalin.  
Dynorphins have high affinity for ĸ-receptors. Dynorphin opioid peptides and their 
receptors exhibits wide spread distribution in mammalian brain and involved in 
numerous functions such as pain regulation, learning process, neuroendocrine function 
and modulation of stress. In many cases dynorphin has no direct action but modulates 
the action of other neurotransmitters such as SP. In the spinal cord dynorphins are 
present in the dorsal horn (47). 
 
1.3.4 Pain mechanism 
1.3.4.1 Ascending nociceptive pathway 
A Noxious stimulus excites thin myelinated Aδ and unmyelinated C-fibres primary 
afferents (48) and induces release of neurotransmitters (e.g., glutamate and substance P) 
from the terminals of theses neurons in the laminae I, II or V of the dorsal horn. These 
released neurotransmitters induce excitation of post-synaptic membrane receptors (e.g, 
glutamate receptors) of the dorsal horn neurons (49, 50).  The pain sensation is then 
transmitted through the spinothalamic tract to the thalamus and is then conveyed to 
various areas of the brain such as the cortex and the hypothalamus. The spinothalamic 
tract is mainly a crossed path, originating from neurons located in the dorsal horn 
Rexed´s lamina I and V and terminating in several different thalamic nuclei, including 
the ventral posterior lateral (VPL) nuclei (51).  
 
1.3.4.2 Descending nociceptive pathway  
From brainstem nuclei, impulses ‘descend’ into the spinal cord and influence the 
transmission of pain signals at the dorsal horn (52, 53). Concerning descending 
inhibition, the periaqueductal grey matter (PAG) is a key region. It projects to the 
rostral ventromedial medulla (RVM) and receives inputs from the hypothalamus, 
cortical regions and the limbic system (53). Neurons in the RVM then project to the 
dorsal horn and through motor neurons to the site of injury.  
The immediate reaction to pain is transmitted over the reflex arc by sensory fibres in 
the dorsal horn of the spinal cord and by synapsing motor neurons in the anterior horn. 
This anatomical pattern of sensory and motor neurons allows the individual to move 
away quickly from the pain source. 
 
1.3.5 Inflammatory joint pain 
In inflammatory joint disorders such as RA and OA pain is generally perceived to arise 
from a combination of peripheral and central mechanisms, but emerging data indicate 
that peripheral inflammation involves complex neuroimmune interactions resulting in 
primary hyperalgesia. A large range of inflammatory molecules can directly sensitize 
nociceptors of primary afferent neurons (54, 55) which start to respond to light pressure 
and movements in the working range of the joint. Most of these units are thinly 
myelinated Aδ fibres or unmyelinated C fibres. Finally, initially mechano-insensitive 
fibres (silent nociceptors) become responsive to mechanical stimulation of the joint and 
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contribute to the afferent inflow into the spinal cord during inflammation (56, 57). 
Collectively, these changes provide the afferent sensory basis of joint pain. The 
consequence of these processes is that during inflammatory conditions the nociceptive 
system is activated by normally innocuous and non-painful mechanical stimuli. 
 
Previous studies indicate that central and peripheral neuronal mechanisms play a role in 
inflammatory joint disorders, particularly with regard to inflammation and pain (58). 
Sensory neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP) 
have been demonstrated to participate not only in pain modulation but also in 
inflammatory processes. Previously, an up-regulation of the SP and CGRP in the ankle 
joints and their corresponding dorsal root ganglia was demonstrated in adjuvant 
arthritis (59). The development and progress of joint inflammation in adjuvant arthritis 
was significantly attenuated by using the neurotoxin capsaicin, which specifically down 
regulates sensory innervation (60). The beneficial effects of capsaicin on joint 
inflammation were correlated with reduced levels of SP and CGRP in the ankle joints 
and corresponding DRG. Similarly, it has been reported that methotrexate treatment 
reduces the severity of joint inflammation and destruction, partly due to its inhibitory 
effect on sensory neuropeptides (61). 
 
Chronic pain is a major feature of inflammatory joint diseases and is maintained in part 
by long-lasting neuroplastic changes in the spinal cord. Previous studies demonstrated 
that the ubiquitin proteasome system is one of the systems involved in the maintenance 
of chronic pain by regulating proteins at pre- and post-synaptic levels (see also section 
1.4.2). 
 
1.4 THE UBIQUITIN PROTEASOME SYSTEM (UPS) 
The degradation and processing of cellular proteins is critical for cell survival, growth, 
and cell division. Proteolysis via the proteasome pathway plays important roles in a 
variety of basic cellular processes. These processes are regulation of cell cycle and 
division, modulation of the immune and inflammatory responses, intracellular signaling 
and development and differentiation (62). 
Cellular proteins are mainly degraded in two ways: lysosomal degradation and the 
ubiquitin proteasome system (UPS). Proteolysis in lysosomes is a non-specific process. 
In higher eukaryotes, membrane-associated and extracellular proteins captured during 
endocytosis (e.g. viral, bacterial) are destroyed in lysosomes. Degradation of the vast 
majority (80-90%) of intracellular proteins is via the UPS (63). The UPS degrades 
short-lived proteins under normal metabolic conditions, regulatory proteins or bulk 
degradation of long-lived proteins in the cytosol, nucleus as well as membrane and 
luminal endoplasmic reticulum in eukaryotic cells (62, 64).  
Ubiquitin-mediated degradation of a protein involves two discrete and successive steps:  
[1] Conjugation of multiple moieties of ubiquitin (Ub) to the protein substrate. Multiple 
copies of ubiquitin, a protein of 76 amino acids, bind covalently to available lysine 
residues on target proteins in a three-step process (Figure 3). In the first step Ub is 
activated by the action of E1 (Ub activating enzyme) and E2 (Ub conjugating enzyme). 
The substrate protein is then selectively targeted by the E3 (ubiquitin ligase) which 
ubiquitinates the protein. Further Ub molecules are added on to create a polyubiquitin 
chain.  
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[2] Recognition of polyubiquitinated proteins are by the 19S proteasome complex. Ub 
chain is cleaved by deubiquitinated enzymes (DUB), substrate protein is unfolded and 
enter into the 20S core for degradation. The substrate proteins are cleaved into smaller 
peptide chains (5-20 amino acids), which are further degraded into constituent amino 
acids and are recycled by the cell (62). The polyubiquitin chain is also broken down by 
the hydrolase enzymes and free Ub molecules are recycled by the cell (Figure 3) (65).  
 
 
 
Figure 3. The ubiquitin-dependent degradation of protein 
 
This process has been named the “ubiquitin-dependent degradation of protein” and was 
first discovered by A. Ciechanover, A. Hershko, and I. Rose who were later awarded 
the Nobel Prize in 2004 (66).  
 
1.4.1  Proteasome Structure 
The proteasome is a cylindrical shaped structure with a molecular weight of 1,500 to 
2,000 kD, consists of two 19S regulatory complex and a core 20S catalytic complex 
(Figure 4). Hence it is also denoted the 26S proteasome (67, 68).  
 
 
 
Figure 4. The 26S proteasome 
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1.4.1.1 The 19S proteasome subunit 
Ubiquitin-tagged proteins are recognized by the 19S regulatory complex, where the 
ubiquitin tags are removed (Figure 4). ATPases with chaperone-like activity at the 
base of the 19S regulatory complex then unfold the protein substrates and feed them 
into the inner catalytic compartments of the 20S proteasome cylinder (69, 70). The 
opening into the 20S catalytic chamber is small (approximately 1.3 nm), and 
significant unfolding of the substrate is required for successful entering into the 20S 
subunit (71). A molecular gate (N-terminal tail of the 3-subunit) also guards the 
opening, but it is constitutively open when the 19S regulatory units are bound to the 
20S proteasome (72). 
 
 
1.4.1.2 The 20S proteasome subunit 
It consists of two outer and two inner rings that are stacked to form a cylindrical 
structure with three compartments (68, 73). Each outer ring has seven alpha-subunits 
( 1 to 7), whereas each inner ring contains seven beta-subunits (ß1 to ß7). The 20S 
proteasome complex has chymotryptic, tryptic, and peptidylglutamyl-like activities (63, 
67). It is conformationally flexible with active catalytic sites located on the inner surface 
of the cylinder where protein substrates bind. Proteins unfolded and without Ub tag, 
enter the inner chamber and are hydrolyzed by six active proteolytic sites on the ß-
subunits (two sites each on the ß1-, ß2-, and ß5-subunits) into small polypeptides 
ranging from three to 22 amino acids in length. Proteins cannot enter the inner cylinder 
through the outer walls of the 20S proteasome because the gaps between the rings are 
tight (Figure 5) (71, 73, 74).  
 
Figure 5. The 20S proteasome 
 
 
1.4.2 The UPS and the CNS 
In the CNS, the 26S proteasome is present in neurons, glia and synapses and regulates 
neuronal signalling, synapse formation and function (75). UPS regulates synaptic 
functions by controlling levels of pre-synaptic proteins (76). At the post-synaptic levels 
the UPS regulates the surface expression and internalization of NMDA- and AMPA-
glutamate receptors (77).  
 
1.4.3 The UPS and NF-ĸB activation 
The UPS plays an essential role in the activation of transcription factor-ĸB (NF-ĸB) 
through proteolytic degradation of inhibitory protein IĸB. NF-ĸB is a heterodimer 
composed of p50 and p65 subunits, and in non-stimulated cells NF-ĸB is retained in the 
cytoplasm in a latent form associated with inhibitory protein IĸB. Following exposure 
of the cell to a variety of extracellular stimuli such as cytokines, viral and bacterial 
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products and stress, IĸB is rapidly degraded by the 26S proteasome and the active 
heterodimer is translocated into the nucleus where it activates the transcription of 
corresponding genes (Figure 6) (78). NF-ĸB promotes transcription of genes which  
 
 
Figure 6. The activation pathway of NF-ĸB. 
 
 
encode cytokines (TNF-α, IL-6, IL-1), stress response factors (Cyclooxygenase-2, NO), 
cell cycle regulators and anti-apoptotic proteins (IAP-1, Bcl-2 family) (79). It is 
believed that the pathological activation of NF-ĸB is a cause of many inflammatory 
diseases and has been an important target for therapeutic drug research in recent years 
(80). 
 
 
 
1.4.4 The UPS and Diseases 
With the broad spectrum of protein substrates and the complex enzymatic machinery 
involved in targeting them and practically all intracellular processes including cell cycle 
control, transcription, translation regulation, cell response to stress being controlled by 
he UPS, it is not surprising that the proteasome pathway is involved in the 
athogenesis of malignant, autoimmune, and neurodegenerative diseases.  
t
p
 
 
1.5 PROTEASOME INHIBITION  
Proteasome inhibitors have provided a valuable research tool for studying the role of 
proteasome in cellular function and disease. Proteasome inhibition has considered as a 
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potential remedy for cancer, inflammation-related disorders and neurodegenerative 
diseases.  
 
The UPS play a significant role in the degradation of regulatory proteins required for 
cell cycle progression and mitosis (62). A disruption in the regulation of these cell cycle 
proteins results in abnormal cell division and tumorogenesis (81). Proteasome 
inhibitors can cause cellular apoptosis in proliferating cancer cells by affecting various 
short-lived proteins, resulting in inhibition of NF-ĸB activity, increased activity of p53 
and Bax proteins, and accumulation of cyclin- dependent kinase inhibitors p27 and p21 
(17, 18). Preclinical studies show that malignant, transformed, and proliferating cells 
are more susceptible to proteasome inhibition than cells in a resting state (82, 83). 
 
Bortezomib is the first inhibitor of the ubiquitin-proteasome pathway to enter clinical 
studies (84, 85). On the basis of a large, multicenter phase II clinical trial in which 
approximately one third of patients with advanced multiple myeloma (MM) had a 
significant response to therapy with bortezomib, on May 13th 2003, the US Food and 
Drug Administration granted approval for use of this drug in the treatment of patients 
with MM (86). The promising preclinical and clinical activity exhibited by bortezomib 
in MM and non-Hodgkin lymphomas (NHL) has confirmed the proteasome as a 
relevant and important target in the treatment of cancer. Several proteasome inhibitors 
are tested and are in pre-clinical and clinical phase (Table 4). 
 
Table 4. List of proteasome inhibitors currently in pre-clinical and clinical testing (81).  
Reagent Clinical trials/status 
Bortezomib (Velcade, 
PS341) 
FDA approved for relapsed and refractory MM.  
Phase II trials in non-Hodgkin lymphomas (NHLs). 
MLN519(PS-519) Phase I trial completed. 
 Intended for acute stroke and myocardial infarcation. 
Epoxomicin Pre-clinical 
Ritonavir  Pre-clinical 
 Approved for HIV treatment 
Phase II studies in tumour patients to be started 
 
 
1.5.1 Toxicity  
The clinical application of proteasome inhibitors might be limited due to potential side- 
effects of available compounds following chronic administration. Toxic affects might 
result from the accumulation of ubiquitinated proteins after inhibition of the 26S 
proteasome. The proteasome inhibitor bortezomib induced mild-to-moderate 
neurotoxic effects in rats (88) and peripheral sensory neuropathy in cancer patients that 
were given this compound chronically (89). The features of bortezomib neuropathy are 
characteristic for a small fiber neuropathy and are characterized by a more sensory than 
motor neuropathy. Thus there is a need for a non-toxic proteasome inhibitor. 
 
1.6 UPS AND INFLAMMATORY JOINT DISORDERS  
As discussed earlier (section 1.4.3) UPS regulates NF-ĸB activation, which in turn 
promotes the expression of a variety of target genes involved in apoptosis and 
inflammation. In particular, an increase in the activity of NF-ĸB has been associated 
with the up-regulation of pro-inflammatory genes involved in several inflammatory 
conditions (78, 90).  
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The activation of NF-κB has been studied in several animal models of arthritis (91) and 
in the synovium of RA patients (92). Furthermore, the activation of NF-ĸB is 
implicated in the pathogenesis of RA (93, 94).  An increased level of proteasome is 
present in serum in patients with different autoimmune diseases and is considered as a 
clinical marker of disease development (95, 96).  
 
Elevated levels of MMP-1 (collagenase-1) in the synovial fluid and serum of RA 
patients (97, 98) and MMP-3 (stromelysin) in the synovial fluid from patients with both 
RA and OA have been determined (99). MMPs, especially MMP-3, are involved in the 
pathogenesis of OA through its ability to degrade proteoglycans (99, 100). 
Interestingly, it has been reported that NF-κB regulates synthesis of MMPs (101).  
 
Progressive destruction of bone and articular cartilage plays a pivotal role in the 
pathogenesis of RA and OA. Previous studies have revealed that osteoclasts are 
responsible for bone destruction. NF-κB is essential for osteoclast formation and 
survival through the nuclear factor κB ligand (RANKL) pathway (102, 103). Abnormal 
activation of NF-κB signalling in osteoclasts has been observed in osteolytic 
conditions, including arthritis, Paget's disease of bone, and periodontitis (104). 
Inhibition or deletion of RANKL prevents bone destruction (103, 105). 
 
1.6.1 Proteasome inhibition and inflammatory joint disorders 
 
Proteasome inhibitors exhibit anti-inflammatory and anti-proliferative effects. Their use 
in diseases characterized by these processes is thought to be promising but still the 
effects of proteasome inhibitors on the pathogenesis of inflammatory join diseases is 
quite limited.   
 
Proteasome inhibitors mainly regulate inflammation by inhibiting NF-ĸB activation. 
The inhibitors fulfill their task via a dual action: they sterically hinder the nuclear 
localization of NF-ĸB, thus retaining them in the cytosol in an inactive form bound to 
the inhibitory protein IκB, and block UPS-mediated processing of the p105 precursor 
to mature p50, which is a subunit of mature NF-κB. It has been observed that the 
inhibition of IκB reduces the severity of experimental arthritis (106). 
  
The chondroprotective role of the proteasome inhibitor MG132 has been reported in 
one study in vitro and in a rat model of OA (107). The proteasome inhibitor bortezomib 
has been demonstrated to suppress human osteoclast formation and to promote 
maturation of osteoblasts (108, 109). Moreover, the proteasome inhibitor MG132 
attenuates TNF- -induced expression of MMP-3 in chondrocytes.  However, the role 
of proteasome inhibitors in regulating RA and OA progression as well as modulating 
the clinical symptom, especially pain, is still unknown. 
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2 HYPOTHESIS AND AIMS OF THE THESIS  
Our hypothesis is that transcription factor NF-κB critically regulates pain and 
inflammation in the inflammatory joint disorders. The neurogenic component of this 
regulation involves the expression of pro-nociceptive dynorphins and sensory 
neuropeptides.  
 
With aim to test this hypothesis and to expand the knowledge about pain and 
inflammatory mechanisms in RA and OA the present study was designed.  
 
More specifically, the aims of the study were: 
1. To investigate the occurrence, localization and distribution of mediators of pain 
and inflammation in peripheral tissues and in the peripheral and central nervous 
system (Paper 1-4). 
2. To assess a relationship between mediators of pain and inflammation with 
nociception and arthritis severity in RA and OA (Paper 2-4). 
3. To explore the role of the transcription factor NF-κB in regulation of pain in 
bone and joint tissues, in addition to its regulation of inflammation. (Paper 2-3). 
4. To analyze the effects of a reversible proteasome inhibitor, MG132, on pain and 
inflammation in RA and OA (Paper 2-4). 
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3 MATERIALS AND METHODS 
 
3.1 ANIMAL MODELS OF ARTHRITIS 
Experimental animal models have contributed tremendously to recent advances in the 
understanding of immunopathology of arthritis. In addition to provide basic insight into 
arthritis, animal models continue to provide the means to test novel experimental 
approaches for treatment. In this thesis, the potential ameliorative effects of the 
proteasome inhibitor MG132 (N-carbobenzoxyl-Leu-Leu-leucinal) on RA and OA are 
studied in two different rat models; adjuvant-induced arthritis and monosodium 
iodoacetate-induced osteoarthritis. 
 
3.1.1 Adjuvant-induced Arthritis 
To study pathogenesis of disease and to evaluate potential anti-arthritic drugs for 
clinical use several experimental models of arthritis have been developed in rats, mice, 
rabbits and monkeys. Most commonly used animal models include rat adjuvant arthritis 
(AIA), rat type II collagen arthritis (CIA), mouse type II collagen arthritis (CIA) and 
antigen induced arthritis in several species. Few spontaneously developing arthritis 
models such as DBA/1 male mice as well as some transgenic mouse models are also 
used (110). 
 
In order to study the effect of MG132, the adjuvant-induced arthritis (AIA) rat 
model was used, which is a well accepted and most frequently used rat model of 
rheumatoid arthritis (RA) since early sixties (111, 112). In RA, there is a strong 
association of the immune system and the pathophysiology of disease. A similar 
association between the immune response induced by the complete Freund´s adjuvant 
and disease occurs in AIA. A single subcutaneous injection of a suspension of heat-
killed Mycobacterium butyricum in paraffin oil into the base of the tail produces intense 
inflammation in joints, with accumulation of neutrophils, monocytes, macrophages and 
T cells in the synovium and synovial fluid (113-115). The inflamed, expanding 
synovium can develop into a pannus tissue, which attaches to and erodes cartilage and 
bone due to the release of proteases, hydrolases and cytokines from the leukocytes and 
synoviocytes (115-117). The pain, synovial hyperplasia, inflammation and destruction 
of cartilage and bone and even neurobiological changes in AIA resemble those that 
have been described for RA (118). Further, the AIA constitutes the only laboratory 
animal model of chronic pain that has been validated to a significant extent (119) and 
the AIA is one of the best-characterized experimental models in which to study the 
activity of anti-arthritic agents.  
 
3.1.2 Monosodium iodoacetate-induced Osteoarthritis 
Animal models of OA are used to study the pathogenesis of cartilage degeneration and 
to evaluate potential anti-arthritic drugs for clinical use. These include naturally 
occurring OA in knee joints of guinea pigs, mice, cows and horses. Surgically induced 
OA include medial meniscal tear in guinea pigs, rats, rabbits and dogs. Chemically 
induced cartilage degeneration by intra-articular iodoacetate injection and transgenic or 
knockout mouse models with defects in the expression of transcription factors, MMPs, 
angiogenic factors, or ECM proteins have provided insight into the mechanisms that 
control cartilage development (120-122).  
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The monosodium iodoacetate (MIA) model used in the present work is 
considered as a reliable and consistent experimental OA model with cartilage 
degeneration and pain that mimics pathological changes in OA patients. The MIA-
induced OA is one of the best-characterized experimental models to study effects of 
drugs on the pathology of osteoarthritis (123). The injection of the metabolic inhibitor 
MIA into a knee joint of rats inhibits glyceraldehyde-3-phosphate dehydrogenase 
activity in chondrocytes, resulting in disruption of glycolysis and eventually cell death. 
The progressive loss of chondrocytes results in histological and morphological changes 
of the articular cartilage and a pain related behavior, closely resembling those seen in 
osteoarthritis patients.  
 
The initial period of knee swelling in MIA-induced OA implies a transient 
synovial inflammation, which may have clinical correlation with early synovial 
inflammation that predicts development of OA in the knee (124). It is then resolved for 
the remaining duration of the study, whereas in the human disease, recurrent 
inflammatory phases are noted. Free nerve endings have been identified in rat (125) and 
human (126) synovium and probably play an important role in joint pain sensation. 
 
3.2 CLINICAL EVALUATION OF EXPERIMENTAL ARTHRITIS 
3.2.1 Inflammation  
Disease progress can be graded in different ways. Most common is to evaluate the 
number of affected joints in each paw. This correlates with the evaluation system used 
for human arthritis patients and grade both redness and swelling. Other methods of 
evaluation are also possible, such as the measurement of swelling over the ankle or 
tarsus joints or measurement of total paw swelling. 
 
The severity of arthritis was evaluated by a scoring system in the adjuvant arthritis 
model (Paper 2). The basis for the system is a clinical evaluation of the affected paws. 
The severity of inflammation in each paw was graded (1-3) by two observers without 
knowledge of the treatment for redness and paw swelling. The total score was the 
cumulative value for four paws, with a maximum of 12 for each rat. Rats were 
considered to be arthritic if the paw score was above 2. 
 
In OA model (Paper 4) inflammation was evaluated by measuring the swelling of right 
and left knee joints recorded at the anterior posterior position using a digital calliper 
(Limit, UK). Joint swelling was measured in mm and was determined as the ratio 
between the left and right knee joints.  
  
3.2.2 Pain  
Assessing the level of pain in animals is a key element in pain research. Current pain 
assessment techniques are mainly limited to estimate animal responses elicited by 
stimuli to the, presumably, affected area using thermal, tactile and mechanical stimuli. 
These responses are invariably reflexive in nature, and are informative only about the 
thresholds of the sensory variables being probed; thermal, tactile, or mechanical. These 
thresholds are obviously important in the assessment of painful states, but are not the 
complete perceptual pain experience from a whole organism perspective.  
 
The hind paw withdrawal threshold (PWT) to mechanical pressure was assessed with 
an algesimeter (Ugo Basile, Italy). A wedge-shaped pusher was applied to the dorsal 
surface of the hind paw at a steadily increasing pressure. The PWT was determined 
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when the animal removed the foot from the apparatus, and the pressure, in grams, 
necessary to evoke paw withdrawal was recorded. A cutoff threshold of 220 g was 
preset to prevent tissue damage. Before measuring the baseline values, the rats were 
habituated to the algesimeter. All measurements were made by two observers without 
knowledge of the treatment regimen (Paper 2, 4). 
 
3.2.3 Bone and cartilage destruction 
Destruction of bone and cartilage was assessed in AIA and in MIA-induced OA by 
radiology and histological analysis using a semi-quantitative grading scoring system.  
 
3.2.3.1 Radiology 
Radiographs of ankle (AIA) and knee joints (OA) of anesthetized rats were taken with 
the help of a dental X-ray machine (Heliodent DS, Siemens AG, Bensheim, Germany). 
X-ray films were developed and scanned with a HP ScanJet II scanner (Hewlett-
Packard, Singapore) and saved into a computer. Lateral view radiographs of ankle 
joints (Paper 2) were evaluated by two observers without knowledge of treatment for 
osteoporosis, cartilage loss and for bone erosion using a subjective 0-3 grading scale 
where 0 = normal, 1 = mildly, 2 = moderately, and 3 = severely affected joint. 
  
Knee radiographs (Paper 4) were taken from the anterior-posterior and lateral views of 
joints and analysed for thinning of joint space, severity of subchondral bone sclerosis 
and osteophyte formation using a scale 0-3.  
 
3.2.3.2 Histology 
Ankle joint. Bilateral hind ankle joints (AIA) were stained with haematoxylin and eosin 
to assess the pathological changes in the ankle joints and to monitor the effects of 
MG132 treatment (Paper 2). Pathological changes in the ankle joint were scored (0-3) 
by two observers without knowledge of treatment and were assessed according to the 
cartilage destruction and bone erosion, and inflammation of the synovium.  
 
Knee Joint. Knee joints (MIA) were stained with toulidine blue and hematoxylin and 
eosin (Paper 4). Histological evaluation was performed by two observers without 
knowledge of treatment on the weight-bearing area of the medial femoral condyle and 
graded on a scale of 0-14, using the Mankin scoring system. Mankin scoring system, 
which was developed for the assessment of human articular cartilage, has also been 
used for grading of animal cartilage. This system assesses changes in structure (0-6 
points), cellular abnormalities (0-3 points), matrix staining (0-4 points) and tidemark 
integrity (0-1), with a maximum of 18 points per section (127, 128).  
 
Pathological changes in the synovium from knee joint was scored and assessed 
according to the synovial lining layer and the subsynovial tissue with a maximum of 18 
points per section. The synovial lining layer was scored according to; hyperplasia of 
synovial lining cells (0-3 points), hypertrophy of synovial lining layer (0-3 points), and 
infiltration of inflammatory cells (0-3 points); and the subsynovial tissue were analyzed 
as: proliferation of granulation tissue (0-3 points), vascularization (0-3 points), and 
infiltration of inflammatory cells (0-3 points) (128). 
 
3.3 BIOCHEMICAL TECHNIQUES USED IN THIS THESIS 
Detailed description of radioimmunoassay (Paper 1), in Situ hybridization (Paper 1), 
Western Blotting (Paper 1), electro mobility shift assay (Papers 2, 3), quantitative RT-
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PCR (Papers 3, 4) and immunohistochemistry (Papers 1-4) can be found in the 
individual papers. 
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4 RESULTS AND DISCUSSION 
 
4.1 DISTRIBUTION OF PRODYNORPHIN IN THE RAT CNS  
Paper 1 
 
Up-regulation of PDYN mRNA and mature dynorphins (DYNs) has been detected in 
animal experiments under conditions of neuropathic, cancer and inflammatory pain 
(129, 130) suggesting the pro-nociceptive role of these peptides. In these and other 
previous studies, the DYN system has been studied at the levels of mRNA and mature 
peptides but not at the protein precursor levels. In our first study we analyzed cellular 
localization and distribution of PDYN, the protein precursor to dynorphins in rat brain, 
and regulation of PDYN cleavage to mature proteins in response to external signals. 
We assume that this approach would characterize regulation of the PDYN biogenesis 
that is relevant for regulation of pain transmission and perception. 
 
The PDYN distribution pattern in the rat brain as determined by IHC and western 
blotting was similar to that of DYN peptides. This distribution was generally consistent 
with previous analyses of DYNs with the highest levels being observed in the 
amygdala, hippocampus and stratum, with lower amounts in the cerebral cortex (131, 
132).  
 
PDYN in an unprocessed form was also detected in brain structures such as the ventral 
trigeminal area (VTA) and the hypocampal CA3 regions that do not have cell bodies of 
neurons producing PDYN but that contain axons and axon terminals originating from 
PDYN-ergic neurons in the ventral strianum and dentate gyrus, respectively. Using 
western blotting it was revealed that PDYN was present in all four regions (dentate 
gyrus, CA3 region of the hippocampus, nucleus accumbens and VTA) and that its 
levels in the VTA and CA3 regions of the hypocampus were slightly lower than those 
in the ventral straitum and dentate gyrus, respectively (Figure 7A, B).   
 
 
Figure 7. Molar content of PDYN and mature neuropeptides (Dyn A, Dyn B, and 
Leu-enkephalin-Arg) in rat dentate gyrus and striatum where somata of PDYN-
containing neurons are located and in CA3 subfield of hippocampus and VTA that 
both contain only projections of PDYN-containing neurons by A) WB and B) RIA. 
 
 
In situ hybridization detected negligible levels of PDYN mRNA in the CA3 and VTA 
regions. Taken together, our results confirm that the precursor was not locally 
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synthesized in these regions and PDYN is transported to and stored in axon terminals. 
To our knowledge, this is the first study indicating non-classical role of PDYN. Further, 
it was observed that PDYN form insoluble oligomers stabilized by disulphide bonds 
that possibly represent the storage form of the protein in secretary granules in the axon 
terminals and dendrites. 
 
The best scenario would have been to analyse PDYN in the brain during inflammatory 
conditions. The spinal cord reflects an extension of the CNS and has traditionally been 
used to analyze pro-nociceptive mediators in inflammatory conditions (130). The 
occurrence of DYNs in some C-fibers and co-localization of DYNs with SP and CGRP 
in the spinal dorsal horn has been previously indicated (133). In addition, it has been 
demonstrated that DYN up-regulation is a necessary event in the maintenance of 
neuropathic pain (134). The expression of endogenous opioid peptides and their 
receptors in bone and joint tissues and their co-existence with sensory neuropeptides in 
peripheral nerves (135, 136) signifies their role in inflammatory joint diseases. DYNs 
may be regulated at the transcriptional level, due to stimulation of the processing of the 
precursor molecule, or inhibition of degradation of these peptides. In this study we 
addressed the possibility of regulation of DYN at the post-translational level.  
 
At axon terminals PDYN may be processed to mature peptides prior to their release 
from secretary granules or secreted as intact precursors. To test this, MIN6 cells were 
stimulated and total levels of the mature peptide in cells and medium were elevated in 
the presence of a high concentration of K+.  The K+ -evoked depolarization of PDYN 
producing cells increases the total amount of DYNs in cells and medium demonstrating 
that PDYN processing is activated. Depolarization of neuronal cells stimulated 
processing of PDYN into DYNs and Leu-enkephalin-Arg. Stimulation of PDYN 
processing in axon terminals and dendrites by neuronal activity and extracellular 
signals may represent a mechanism for the local regulation of synaptic transmission. 
This mechanism may be relevant for several neuropathological conditions, including 
neuropathic and inflammatory pain.  
 
One of the systems actively involved in synaptic transmission and processing and 
stimulated secretion of synaptic proteins including DYNA and CGRP release and 
postsynaptic actions of DYNA is the UPS (137).  
 
4.2 ROLE OF UPS ON PAIN AND INFLAMMATION IN ADJUVANT-
INDUCED ARTHRITIS 
Papers 2 and 3 
 
In the second and third study we investigated the role of the UPS in chronic joint 
inflammation and inflammatory pain by systemically inhibiting this system in adjuvant 
arthritis. UPS plays an essential role in the activation of transcription factor NF-ĸB 
which is involved in the expression of pro-inflammatory mediators such as cytokines 
and cell adhesion molecules (138). In addition, UPS regulates synaptic functions by 
controlling levels of pre- and post-synaptic proteins under normal conditions and is 
required for the maintenance of neuropathic and pathological pain induced by sustained 
morphine exposure (87, 139). However, the information about the role of UPS in the 
pathogenesis of chronic arthritic conditions is scarce. 
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The activation of NF-ĸB, in arthritic ankle joints, was investigated by IHC and EMSA. 
Our results indicate an increase in p50 (a subunit of NF-κB) positive cells in the 
synovium and in cartilage during arthritis.  Our results are in accordance with previous 
observations indicating an increase in the p50 and p65 positive cells in experimental 
model of arthritic (91), and in synovium from RA patients (93, 94). Moreover, we 
observed an increased DNA-binding activity of NF-κB and p50 in arthritic joints.  
Repeated subcutaneous administration of reversible proteasome inhibitor MG132 at the 
onset of arthritis, significantly down-regulated the severity of arthritis as indicated by 
reduced arthritis index (Figure 8A) and the p50 expression and DNA binding activity 
of both NF-κB and p50 homodimers in arthritic rats. Our results verify that activation 
of NF-κB contributes to the pathogenesis of arthritis and an early intervention could 
give promising results. Further, our results confirm that the processing of the p100 
precursors into mature p50 subunits is regulated by the UPS. 
 
 
 
Figure 8. Effects of proteasome inhibitor MG132 on (A), arthritis index and (B), on the 
hind paw withdrawal threshold (PWT) on day 28. 
 
In order to study UPS effects on pain, SP and CGRP expression was studied in the 
periosteum and synovium of arthritic ankle joints; these are structures that are pain- 
sensitive and prone to inflammation. The increased SP and CGRP expression coincided 
with decreased pain thresholds as measured by paw withdrawal threshold (PWT) in 
arthritic rats (Figure 8B). It has been implicated that joints that developed severe 
arthritis had a higher density of innervations by SP-containing sensory neurons, and a 
higher SP content, than joints that developed mild arthritis (140). Neural depletion of 
SP by capsaicin eliminates paw swelling and tenderness within the inflamed joint 
(141). Correspondingly, MG132 increased PWT in arthritis rats and levels of SP and 
CGRP were down-regulated in arthritic joints indicating that UPS regulates 
inflammation induced pain behaviour. Thus, our results show for the first time that 
UPS-mediated protein degradation likely is involved in peripheral sensitization. In 
addition they verify that SP and CGRP expression is UPS mediated. Interestingly, it 
has been observed that proteasome inhibitors MG132 and epoxomicin can prevent the 
development of behavioural signs of neuropathic pain and abolish abnormal pain 
induced by sustained morphine exposure (87, 142) These compounds inhibited the 
release of DYNA and CGRP and normalized molecular changes in the spinal cord 
contributing to central sensitization (87, 142). 
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Our radiographic and histological analysis revealed that the subchondral bone 
resorption which is a characteristic feature of adjuvant arthritis was mitigated by 
MG132. MG132 possibly prevented bone resorption by interfering osteoclast 
activation through the RANKL signalling pathway that is under control of NF-κB 
(102). This assumption is supported by recent in vitro and in vivo studies indicating that 
the proteasome inhibitor bortezomib directly suppressed human osteoclast formation 
and promoted maturation of osteoblasts (108, 109). Thus, our results suggest that 
targeting of UPS by MG132 reduces pain and inflammation and bone destruction in 
adjuvant arthritis. 
 
Paper 3 
 
In this study we further explored the role of UPS on molecular changes in the DRG and 
in the spinal cord, by systemically inhibiting this system in adjuvant arthritis. The DRG 
and the spinal cord actively participate in the peripheral and central sensitization.  
 
It has been previously demonstrated that proteasome inhibitors MG132 and 
epoxomicin can both prevent the development of behavioural signs of neuropathic pain 
and abolish abnormal pain induced by sustained morphine exposure (134, 135). These 
compounds also inhibited the enhanced DYN and CGRP release and reduced central 
sensitization by normalizing molecular changes in dorsal horn neurons (137). 
Inflammatory and neuropathic pain activates similar central neuronal mechanisms and 
neurotransmitters from the primary afferents including SP and CGRP. We aimed that 
proteasome inhibitors used to treat experimental neuropathic pain may also be 
successful for the treatment of inflammatory pain. 
 
PCR and IHC analyses revealed a significant increase in the synthesis and expression 
of SP in the DRG and in the spinal cord in arthritic rats. In the spinal cord, SP positive 
nerve fibers were identified in the dorsal horn of the spinal cord, predominantly in 
lamellae I, II, and a few in the deep layers. Up-regulated SP expression correlates with 
arthritis severity and nociceptive behavior of arthritic rats. This concord with previous 
observations that the altered expression of SP and CGRP is critical for the modulation 
of pain and inflammation (141, 143).  
 
Interestingly, no change in PDYN expression was observed in the DRG neurons of 
arthritic rats by PCR or IHC. In contrast, strong up-regulation in PDYN gene 
expression was observed in the spinal cord. IHC analysis revealed PDYN 
immunoreactivity in lamellae I, II and V. Our results are in agreement with previous 
observations indicating that peripheral inflammation induces a dramatic up-regulation 
of PDYN biosynthesis in nociceptive neurons of the spinal dorsal horn (133, 144). 
MG132 treatment reversed the up-regulated expression of SP both in the DRG and in 
the spinal cord of arthritic rats and PDYN expression in the spinal cord.  
 
Our data suggest that MG132 exert its anti-inflammatory and anti-nociceptive 
responses by the attenuating SP expression in DRG neurons and SP and PDYN 
expression in the spinal dorsal horn. Our findings indicate that effects of proteasome 
inhibitor MG132 on chronic inflammatory pain are mediated through several protein 
systems, including those controlling dynorphin and sensory neuropeptides SP and 
CGRP release. Thus, by the use of an inhibitor of the UPS we propose that the UPS 
acts directly in the DRG in the spinal cord, in addition to its effect in the joints. 
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4.3 EFFECTS OF UPS INHIBITION ON OSTEOARTHRITIS PAIN AND 
DISEASE PROGRESSION 
 
Paper 4 
 
In this study we investigated the effects of MG132 on OA pain and disease progression 
in the MIA-induced OA model. To our knowledge, this is the first report of the effects 
of UPS inhibition on OA pain. Mechanisms of pain in OA are still unclear but probably 
contributed by sensitization of nociceptors in the synovium and subchondral bone. The 
aim was to study the role of UPS in OA pain and on disease progression.  
   
In OA rats, radiographic and histological analysis revealed that pathological changes 
in knee joints, loss of proteoglycan and thinning of the articular cartilage were similar 
to human OA. Biochemical analysis indicated an up-regulation in the expression of 
matrix metalloptoteinase-3 (MMP-3) in the cartilage, MMPs has ability to degrade 
proteoglycans, and may be involved in the pathogenesis of OA (100, 101). An 
increased expression of SP and CGRP in inflamed knee joints was observed, 
especially in the synovium and in the subchondral bone, and coincided with 
decreased pain thresholds in OA rats. Administration of MG132 reversed pain 
behaviour and the expression of MMP-3 altered during OA.  
 
Our observations, indicating a chondroprotective role of MG132 in OA, concord with 
previous in vitro and in vivo studies (107) and further explore that the 
chondroprotective role of MG132 probably is mediated through decreased MMP-3 
expression in OA cartilage. Interestingly, MMP-3 synthesis is regulated by the NF-κB, 
the activation of which is under the control of UPS. However, it has been reported 
earlier that proteasome inhibitors, bortizomib and MG262 can induce apoptosis in 
proliferating chondrocytes in the growth plate of young mice (145) emphasizing the 
need of further studies to scrutinize the clinical use of proteasome inhibitors.  
 
The progressive loss of articular cartilage results in subchondral bone exposure. The 
subchondral regions of long bones are highly vascularised (146). The subchondral 
ischemia and increased venous pressure due to subchondral bone exposure as well as 
joint loading may induce the liberation of non-adrenergic/non-cholinergic pain 
mediators such as SP and CGRP in the subjacent bone inducing pain (147). Clinical 
evidence demonstrates that SP and CGRP levels were increased in the capsule of hip 
joints and soft tissues in patients with painful OA (148). MG132 abolished the 
upregulated expression of SP and CGRP especially in subchondral bone in the knee 
joints.  
 
A robust effect with reversal of pain behavior, attenuated cartilage destruction and 
decreased SP, CGRP and MMP-3 expression was observed with MG132 
administration. Thus, these results suggest that the pain and cartilage destruction in OA 
are regulated by the UPS. These findings may be relevant for human OA, paving the 
way to develop a novel pharmacotherapy regulating pain as well as the disease 
progression.  
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
In my thesis work I provide evidence that PDYN in the brain is transported to and 
stored in axon terminals in the CA3 regions of the hypocampus and in the VTA in an 
unprocessed form. PDYN form insoluble oligomers which are stabilized by disulphide 
bonds and possibly represent the storage form of the protein in the axon terminals and 
dendrites. Depolarization of neuronal cells stimulated processing of PDYN into mature 
DYNs and their release. Activation of PDYN processing possibly represents a novel 
mechanism for the local regulation of synaptic transmission in the CNS.  
 
Furthermore, I provide evidence that pain and inflammation in animal models of 
arthritis is regulated by UPS. The severity of arthritis and inflammatory pain is reduced 
by using a synthetic small molecule MG132, which has an inhibitory effect on UPS. 
Moreover, the treatment of arthritic rats by MG132 reversed the up-regulated 
expression of SP and CGRP in the affected joints and SP and PDYN in the DRG and in 
the spinal cord. The disease modifying effects of MG132 was associated with reduced 
NF-κB activation at the site of inflammation as well as in the spinal cord. Probably, by 
selective control of NF-κB activity by proteasome inhibitors in the early stages of RA 
and OA, a better symptoms control could be achieved.  
 
It is known that NF-κB is an important transcription factor involved in a wide range of 
clinical disorders including the inflammatory joint disorders RA and OA. It is 
important to investigate the effects of MG132 on human synovial samples. In 
preliminary studies of human RA synovial samples, we recorded a down-regulation of 
IL-6 production by 80% when MG132 was added to the biopsy culture. In contrast, IL-
8 production was unaffected (Wähämaa and Ahmed, unpublished data, 2010).  Future 
studies to evaluate the effect of MG132 on NF-κB activation and cytokine production 
as well as on the release of SP and CGRP in synovial tissues would provide promising 
results.  
 
In this thesis work I evaluated anti-nociceptive and anti-inflammatory effects of 
MG132 during the early and late inflammatory phase of adjuvant and osteoarthritis. 
The results indicate the probable involvement of UPS both in the early inflammatory as 
well as in late neurogenic phase of pain. Furthermore, our results suggest that the 
beneficial effects of MG132 are mediated probably by regulating the expression of 
dynorphins, SP and CGRP in the DRG and spinal cord and their possible release in the 
peripheral tissues. These results are supported by previous studies indicating that 
proteasome inhibitors MG132 and epoxomicin decreased pain by attenuating DYNA 
and CGRP release in the spinal cord (137, 142). Recently, it has been shown that UPS 
regulates the surface expression and internalization of NMDA- and AMPA-glutamate 
receptors at post-synaptic levels (77). It has been implicated that DYNA-induced 
mechanical allodynia and hyperalgesia can be prevented with NMDA-receptor 
antagonists (149). Future investigations exploring UPS mediated glutamergic 
regulation would help to understand the mechanism behind chronic inflammatory pain. 
 
Molecular changes responsible for pain sensitivity are not restricted to neurons in the 
dorsal horn, and there is growing evidence to suggest the involvement of glia- and of 
glia-neuronal signalling in initiating and sustaining enhancement of nociceptive 
transmission (150). In particular, a role has emerged for microglia in pain 
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hypersensitivity following nerve injury (150). Thus, by expanding the understanding of 
cellular and molecular signalling mechanisms in the dorsal horn, which includes both 
neurons and glia, new strategies targeting UPS will be beneficial to reverse chronic 
inflammatory pain conditions.  
 
In the peripheral tissues selective blocking of nociceptive signals would be an attractive 
approach. Recently, expression of the two main classes of acid-sensing nociceptors, the 
acid-sensing ion channels (ASICs) and the transient receptor potential channel vanilloid 
subfamily member 1 (TRPV1), has been reported in the sensory neurons innervating 
bone (151). The acidic microenvironment created by bone-resorbing osteoclasts 
activates these acid-sensing nociceptors, causing bone pain. Maturation of osteoclasts is 
regulated by the UPS, thus emphasizing the need to target these receptors in peripheral 
tissues.   
 
Present work revealed that MG132 attenuated bone and cartilage destruction in 
adjuvant arthritis and OA in rat. MG132 possibly prevents destructive changes by 
attenuating MMPs expression and by interfering osteoclast activation through the 
RANKL signalling pathway, both processes being under the control of NF-κB (102). 
This assumption is supported by recent in vitro and in vivo studies indicating that 
proteasome inhibitor bortezomib directly suppressed human osteoclast formation and 
promoted maturation of osteoblasts (108, 109). More direct evidence will be required 
to consider use of MG132 as a disease-modifying agent in both RA and OA. 
 
Taking into account that UPS controls important functions in eukaryotic cell, 
proteasome inhibitors could have been considered as toxins without any therapeutic 
value. Unexpectedly, proteasome inhibitors are well-tolerated drugs and do not produce 
adverse effects in normal cells even at high doses. Though, clinical trials indicate that 
use of bortezomib induce peripheral sensory neuropathy in patients (152), that might 
limit its therapeutic use. However, the reversible proteasome inhibitors like MG132 
used in present thesis work apparently did not produced any toxic effects and was well 
tolerated. The use of reversible proteasome inhibitors can therefore be considered as a 
better alternative. It will be a future challenge to develop drugs specifically targeting 
the UPS or more specifically UPS E3 that select proteins for the UPS-mediated 
degradation in order to treat inflammatory joint disorders.   
 
In conclusion, our results suggest that UPS is one of the intracellular pathways that are 
critically involved in the development of joint inflammation and inflammatory pain. It 
is expected that novel and safe proteasome inhibitors with limited adverse effects 
would be available targeting joint changes, pain and inflammation in inflammatory 
joint disorders. 
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